BELTSVILLE, Md., Nov. 01, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will host a Virtual Oncology Pipeline Update Event at 4:30 p.m. ET on Monday, November 15, 2021. During the event, NextCure will provide an update on its oncology pipeline, including data presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting. The event will also feature Roy Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Directo

BELTSVILLE, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the presentation of preclinical data demonstrating that treatment with NC605, a novel anti-Siglec-15 (S15) antibody, resulted in enhanced generation of quality bone with better mechanical properties, in an oral presentation at the Osteogenesis Imperfecta Federation Europe virtual Investigator Meeting on November 15th, 2024. These results demonstrate that NC605 is a highly effective treatment for Osteogenesis Imperfecta (OI), also known as brittle

Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-endCash of approximately $75 million expected to fund operations into second half of 2026 BELTSVILLE, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported third-quarter 2024 financial results. "The November SITC presentation of LNCB74 preclinical data will highlight the differentiation of our B7-H4 ADC from other ADC's that also target B7-H4. We plan to file an IND in the fourth quarter of

Preclinical data for LNCB74 highlights its potential as therapeutic for treating multiple solid tumor indications; Investigational New Drug (IND) application filing expected by year-endAdditional biomarker data support proposed mechanism of action of NC410 BELTSVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today reports pre-clinical data from LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) being developed in partnership with LigaChem Biosciences (LCB) (KOSDAQ: 141080), and biomarker data from t

BELTSVILLE, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced two presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Houston, TX from November 6-10, 2024. NextCure will share pre-clinical data from LNCB74 (B7-H4 ADC) and biomarker data from NC410 combination study with pembrolizumab in ICI-naïve MSS/MSI-L CRC during poster sessions. Poster Presentation Details: Title: LNCB74 is a B7-H4 antibody-drug conjugate with a β-glucuronide linker-MMAE payload system to enha

Of the 20 evaluable ovarian cancer patients, there were 5 PRs Of the 43 evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 3 PRs Biomarker data support proposed mechanism of action of NC410 BELTSVILLE, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab was presented at ESMO 2024. The trial, which is evaluating the combination in ovarian

LNCB74 (B7-H4 ADC) GLP tox studies completed and targeting an IND application by year-endNC410 combo with pembrolizumab ovarian cohort enrollment completedCash of approximately $86.4 million expected to fund operations into second half of 2026 BELTSVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- – NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported second-quarter 2024 financial results. "Following the release of Phase 1b data for the combination of NC410 and pembrolizumab at ASCO, we have completed enrollm

BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on Thursday, June 27, 2024.   A recording of the webcast will be available on the conference day starting at 7 AM ET through the Investors section of the company's website at www.nextcure.com. The webcast will be available on the website for 30 days. About NextCure, Inc.NextCure, Inc. is a clinical-stage biopharmaceutical company

Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51%Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43%Data to be presented June 1, 2024, 9:00 am-12:00 pm CT BELTSVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab will be presen

Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to fund operations into second half of 2026 BELTSVILLE, Md., May 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported its first-quarter 2024 financial results. "We look forward to providing an update on the NC410 combo trial at the ASCO Annual Meeting, which will include data

BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) --  NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, will present a poster on clinical data from the Phase 1b portion of a study evaluating NC410 in combination with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 – June 4 in Chicago. Presentation details: Title: A phase 1b study of NC410 in combinatio

HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and maintains $8 price target.

HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and maintains $8 price target.

Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43%Data to be presented June 1, 2024, 9:00 am-12:00 pm CT BELTSVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab will be presente

HC Wainwright & Co. analyst Emily Bodnar reiterates NextCure (NASDAQ:NXTC) with a Buy and maintains $8 price target.

Needham analyst Gil Blum reiterates NextCure (NASDAQ:NXTC) with a Buy and maintains $4 price target.

NextCure (NASDAQ:NXTC) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.59) by 3.39 percent. This is a 5.17 percent decrease over losses of $(0.58) per share from the same period last year.

Gainers Salarius Pharmaceuticals (NASDAQ:SLRX) shares rose 33.9% to $0.83 during Friday's after-market session. The market value of their outstanding shares is at $3.2 million. Masimo (NASDAQ:MASI) shares rose 12.48% to $151.77. The company's market cap stands at $8.0 billion. Vicarious Surgical (NYSE:RBOT) shares moved upwards by 11.17% to $0.38. The market value of their outstanding shares is at $66.7 million. Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 11.11% to $2.2. The company's market cap stands at $8.0 million. Psyence Biomedical (NASDAQ:PBM) stock increased by 9.09% to $1.2. The company's market cap stands at $16.0 million. Bright Green (NASDAQ:BGXX) shares ro

HC Wainwright & Co. analyst Emily Bodnar maintains NextCure (NASDAQ:NXTC) with a Buy and raises the price target from $5 to $8.

Needham analyst Gil Blum maintains NextCure (NASDAQ:NXTC) with a Buy and maintains $4 price target.

Gainers Yield10 Bioscience (NASDAQ:YTEN) shares moved upwards by 71.5% to $0.42 during Thursday's regular session. The market value of their outstanding shares is at $4.9 million. Monogram Orthopaedics (NASDAQ:MGRM) stock rose 28.74% to $2.15. The market value of their outstanding shares is at $68.0 million. As per the press release, Q4 earnings came out 4 days ago. X4 Pharmaceuticals (NASDAQ:XFOR) stock increased by 21.61% to $1.24. The market value of their outstanding shares is at $207.5 million. As per the news, the Q4 earnings report came out today. Eiger BioPharmaceuticals (NASDAQ:EIGR) shares rose 17.78% to $6.33. The market value of their outstanding shares is at $9.3 million. C

BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board. As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprietary ADCs, including LNCB74 directed to B7-H4. "We are delighted to have Dr. Dixit join our Scientific Advisory Board, where he will leverage his exceptional experience in developing antibody-drug c

BELTSVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Lisa M. Coussens, PhD, FAACR, to its Scientific Advisory Board. As an accomplished translational tumor immunologist whose research is focused on the role immune cells play in tumor development, Dr. Coussens will support NextCure in its efforts to build and develop its proprietary pipeline of immunomedicines. "We are delighted to have Dr. Coussens join our Scientific Advisory Board, where she will leverage

BELTSVILLE, Md., March 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year 2020 financial results and provided a business update. “Our team has worked diligently throughout 2020 to advance our programs despite the difficult environment created by the COVID-19 pandemic. We are thrilled that Dr. Han Myint has recently joined NextCure as our Chief Medical Officer and we are poised to harness his expertise in oncology product development to further advance our product pipe

BELTSVILLE, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Dr. Han Myint, MD, FACP as chief medical officer. Dr. Myint will oversee the clinical development of key products in NextCure’s product pipeline, including NC318, a first-in-class immunomedicine, targeting Siglec-15 (S15), and NC410, recombinant LAIR-2 fusion protein designed to block immune suppression mediated by the immune modulator LAIR-1. Prior to joining NextCure, Dr. Myint held senior roles at both